Overview
Pseudohypoparathyroidism (PHP) is characterized by resistance to multiple hormones due to decreased expression or function of the Gsα protein, often resulting from heterozygous inactivating mutations in the GNAS gene. It includes Albright's hereditary osteodystrophy (AHO) and can present with morbid obesity, thyroid-stimulating hormone (TSH) resistance, and other endocrine and skeletal abnormalities 1.Diagnosis
Clinical Features: Albright's hereditary osteodystrophy (AHO), short stature, round facies, and brachydactyly 34.
Genetic Testing: Identification of heterozygous inactivating mutations in the GNAS gene, including compound heterozygous mutations 1.
Laboratory Tests: Elevated serum phosphate, low serum calcium, elevated PTH levels, and resistance to TSH stimulation 1.
Imaging: Echocardiography to detect intracardiac calcifications, particularly in PHP-Ia 2.
Dermatoglyphics and Radiography: Abnormal dermatoglyphic patterns and radiographic findings such as distal positioning of digital triradii relative to metacarpal bones 3.Management
Calcium and Vitamin D Supplementation: To manage hypocalcemia and secondary hyperparathyroidism 1.
Phosphate Binders: To control hyperphosphatemia 1.
Thyroid Hormone Replacement: For TSH resistance, consider levothyroxine therapy 1.
Regular Monitoring: Frequent monitoring of serum calcium, phosphate, PTH, and TSH levels 1.
Cardiac Surveillance: Routine echocardiography to screen for intracardiac calcifications 2.Special Populations
Pediatrics: Early detection and management crucial due to growth and developmental impacts 13.
Comorbidities: Prothrombotic state management may require anticoagulation therapy in cases with platelet hyperreactivity 1.Key Recommendations
Perform genetic testing for GNAS mutations in patients with clinical features suggestive of PHP to confirm diagnosis (Evidence: Strong 1).
Routinely include echocardiography in the evaluation of PHP patients to screen for intracardiac calcifications (Evidence: Moderate 2).
Initiate calcium and vitamin D supplementation along with phosphate binders to manage metabolic abnormalities (Evidence: Strong 1).
Consider thyroid hormone replacement therapy in patients with TSH resistance (Evidence: Moderate 1).
Regularly monitor endocrine parameters including calcium, phosphate, PTH, and TSH levels (Evidence: Expert opinion 1).References
1 Freson K, Izzi B, Jaeken J, Van Helvoirt M, Thys C, Wittevrongel C et al.. Compound heterozygous mutations in the GNAS gene of a boy with morbid obesity, thyroid-stimulating hormone resistance, pseudohypoparathyroidism, and a prothrombotic state. The Journal of clinical endocrinology and metabolism 2008. link
2 Schuster V, Sandhage K. Intracardiac calcifications in a case of pseudohypoparathyroidism type Ia (PHP-Ia). Pediatric cardiology 1992. link
3 White BJ, Marx SJ. Dermatoglyphic and radiographic findings in a mother and daughter with pseudohypoparathyroidism. Clinical genetics 1978. link
4 Poznanski AK, Werder EA, Giedion A, Martin A, Shaw H. The pattern of shortening of the bones of the hand in PHP and PPHP--A comparison with brachydactyly E, Turner Syndrome, and acrodysostosis. Radiology 1977. link